CLDI

Business Context and Reporting Period

Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Calidi is a biotechnology company developing targeted therapies using its proprietary RedTail platform, an engineered enveloped oncolytic virus designed for systemic delivery to metastatic sites. The company has no approved products and has not generated revenue from product sales. Operations focus on research and development (R&D), clinical trials, and capital raising.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 22% ($2.4 million) compared to the prior year period. General and Administrative (G&A) expenses dropped significantly by 44% ($2.5 million), primarily due to reduced headcount and lower professional fees. R&D expenses remained relatively flat, increasing slightly by 3% ($0.1 million) due to higher drug manufacturing costs.
• Capital Raising: The company raised approximately $7.3 million in gross proceeds during the six months ended June 30, 2026, through a Confidentially Marketed Public Offering (CMPO) and an At-the-Market (ATM) offering.
• Reverse Stock Split: On July 30, 2026, the company effected a 1-for-16 reverse stock split. All share and per-share data in this filing have been restated to reflect this split retroactively.
• Warrant Activity: Significant warrant issuances occurred, including Series J, K, and L warrants in March 2026. Exercise prices for these warrants were reset to $4.00 in April 2026 and subsequently to $1.44 in August 2026 following the reverse stock split.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the date of issuance. The company does not have sufficient cash to support current operations for the next year without additional funding.
• Liquidity Strategy: The company plans to raise additional capital through public or private equity or debt financings. Failure to secure funding could force the company to delay or terminate R&D programs.
• Facility Changes: In July 2026, the company entered into a new lease for a smaller facility (approx. 9,000 sq. ft.) effective October 2026 and terminated its previous larger lease (approx. 15,000 sq. ft.) effective September 2026 to reduce costs.
• Legal Proceedings: The company is involved in consolidated litigation with former executives (Kalajian and Sanchez) regarding employment disputes and unauthorized bonuses, with a trial date set for May 2027. A securities fraud case filed by Mr. Yian Zeng is pending a hearing on a Motion for Summary Judgment.
• Unusual Items: A $0.3 million "deemed dividend" was recorded in Q2 2026 due to the amendment of existing warrant exercise prices, which reduced net loss attributable to common stockholders.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $4.3 million cash balance against the projected burn rate of ~$8.5 million per six months to assess immediate dilution risk.
• Warrant Overhang: Review the terms of the 2.6 million outstanding warrants, noting the recent exercise price resets to $1.44 and the potential for significant dilution if exercised.
• Legal Exposure: Monitor the status of the consolidated employment litigation and the securities fraud case, as outcomes could result in material damages or reputational harm.
• Reverse Stock Split Impact: Confirm the trading volume and price stability of the stock post-split (trading commenced July 31, 2026) to ensure continued compliance with exchange listing standards.
• Financing Terms: Scrutinize the terms of any future financing, particularly given the company's reliance on equity raises which may include warrants or pre-funded warrants with dilutive features.